Skip to main navigation
  • Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Scholar Rock, Inc. Logo

Scholar Rock, Inc.

  • Careers
  • Newsroom
  • Contact Us
  • Patients & Families
    • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access

    Learn about our commitment to creating possibilities for those living with serious disease.

    Patients & Families

  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors

    Meet Scholar Rock, a biopharmaceutical company committed to improving lives.

    Our Company

  • Our Science
    • Our Science
    • Platform
    • Publications & Posters

    Discover how our breakthrough approach treats complex disease at its biological root.

    Our Science

  • Our Pipeline
    • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
    • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Investors & Media
    • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
Link to homepage Investors & Media Financials & Filings

Investors and Media

Financials & Filings

Main content section

Annual Reports

2024 Annual Report
7.07 MB
2023 Annual Report
12.77 MB
2022 Annual Report
3.01 MB
2021 Annual Report
5.25 MB
2020 Annual Report
3.3 MB
2019 Annual Report
4.81 MB
2018 Annual Report
3.22 MB
Filing Date Description Form Filing Group View
February 13, 2024 Statement of changes in beneficial ownership of securities 4
3,4,5
View HTML
0001415889-24-003629.pdf
0001415889-24-003629.rtf
0001415889-24-003629.xls
February 9, 2024 An amendment to the SC 13G filing SC 13G/A
Other
View HTML
0000315066-24-001487.pdf
0000315066-24-001487.rtf
February 9, 2024 An amendment to the SC 13G filing SC 13G/A
Other
View HTML
0001193125-24-030171.pdf
0001193125-24-030171.rtf
0001193125-24-030171.xls
February 9, 2024 An amendment to the SC 13G filing SC 13G/A
Other
View HTML
0001193125-24-030312.pdf
0001193125-24-030312.rtf
0001193125-24-030312.xls
January 26, 2024 A statement of beneficial ownership of common stock by certain persons SC 13G
Other
View HTML
0001086364-24-004850.pdf
0001086364-24-004850.rtf
January 18, 2024 Statement of changes in beneficial ownership of securities 4
3,4,5
View HTML
0001415889-24-001516.pdf
0001415889-24-001516.rtf
0001415889-24-001516.xls
January 18, 2024 Statement of changes in beneficial ownership of securities 4
3,4,5
View HTML
0001415889-24-001521.pdf
0001415889-24-001521.rtf
0001415889-24-001521.xls
January 18, 2024 Statement of changes in beneficial ownership of securities 4
3,4,5
View HTML
0001415889-24-001524.pdf
0001415889-24-001524.rtf
0001415889-24-001524.xls
January 18, 2024 Statement of changes in beneficial ownership of securities 4
3,4,5
View HTML
0001415889-24-001522.pdf
0001415889-24-001522.rtf
0001415889-24-001522.xls
January 8, 2024 Report of unscheduled material events or corporate event 8-K
Current Reports
View HTML
0001157523-24-000027.pdf
0001157523-24-000027.rtf
0001157523-24-000027.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
  • First page «
  • Previous page ‹
  • …
  • Page 22
  • Page 23
  • Current page 24
  • Page 25
  • Page 26
  • …
  • Next page ›
  • Last page »

Data provided by Kaleidoscope.

Primary Sidebar

Investor Menu

  • Investors & Media
  • Press Releases
    • Archived Press Releases
  • Events & Presentations
  • Corporate Governance
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
  • Stock Information
    • Historical Stock Lookup
    • Investment Calculator
    • Analyst Coverage
  • Investor FAQs
  • Contact IR or Media

In this section

Footer

Scholar Rock, Inc.
301 Binney Street, 3rd Floor
Cambridge, MA 02142

Phone: 857.259.3860
info@scholarrock.com

© 2026 All Rights Reserved
  • Community Guidelines
  • Expanded Access Policy
  • Privacy Policy
  • Terms of Use

We are Scholar Rock.

A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.

Learn More About Our Pipeline

  • Community Guidelines
  • Expanded Access Policy
  • Privacy Policy
  • Terms of Use
Scholar Rock, Inc. Logo
  • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access
  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors
  • Our Science
    • Our Science
    • Platform
    • Publications & Posters
  • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
    • Immuno-Oncology
      • Cancer (solid tumors)
      • Fibrotic Diseases
    • Hematology
      • Anemia
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
  • Careers
  • Newsroom
  • Contact Us